Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori.
- Author:
Sang Pil YUN
1
;
Han Gyung SEON
;
Chang Soo OK
;
Kwang Ho YOO
;
Min Kyung KANG
;
Won Hee KIM
;
Chang Il KWON
;
Kwang Hyun KO
;
Seong Gyu HWANG
;
Pil Won PARK
;
Sung Pyo HONG
Author Information
1. Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. sphong@cha.ac.kr
- Publication Type:Original Article
- Keywords:
Helicobacter pylori;
Eradication;
Rifaximin
- MeSH:
2-Pyridinylmethylsulfinylbenzimidazoles;
Amoxicillin;
Bismuth;
Clarithromycin;
Helicobacter;
Helicobacter pylori;
Humans;
Metronidazole;
Ofloxacin;
Rifamycins;
Tetracycline
- From:Gut and Liver
2012;6(4):452-456
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: This study assessed the efficacy of a rifaximin plus levofloxacin-based rescue regimen in patients that had failed both triple and quadruple standard regimens for the eradication of Helicobacter pylori. METHODS: We treated patients for H. pylori between August 2009 and April 2011. The triple regimen consisted of combined treatment with amoxicillin, clarithromycin, and pantoprazole for 1 week. For failed cases, a quadruple regimen of tetracycline, metronidazole, bismuth dicitrate, and lansoprazole for 1 week was administered. The rescue regimen for persistently refractory cases was rifaximin 200 mg t.i.d., levofloxacin 500 mg q.d., and lansoprazole 15 mg b.i.d. for 1 week. RESULTS: In total, 482 patients were enrolled in this study. The eradication rates associated with the first and second regimens were 58% and 60%, respectively. Forty-seven out of 58 patients who failed with the second-line regimen received rifaximin plus levofloxacin-based third-line therapy. The eradication rate for the third regimen was 65%. The cumulative eradication rates were 58%, 85%, and 96% for each regimen, respectively. CONCLUSIONS: A rifaximin plus levofloxacin-based regimen could be an alternative rescue therapy in patients with resistance to both triple and quadruple regimens for the eradication of H. pylori.
